● Resources ● Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial
Important notice regarding use of cookies: Our Privacy Policy reflects our use of cookies to collect and process data. By continuing to use this website, you agree to use our cookies and similar technologies as described in our Privacy Policy.